|
|
 |
| NovoSeven® RT is used to treat bleeding episodes in people with hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with resistance to platelets, and acquired hemophilia. |
|
|
|
 |
|
| Trust the facts. |
Be confident in your
treatment choice. |
|
|
|
|
|
 |
NovoSeven® RT has over 30 years of clinical and real-world experience in people with hemophilia B with inhibitors.a |
|
|
 |
| SEVENFACT DOES NOT |
| It was studied in two people with Hemophilia B with inhibitors in the PERSEPT 1 clinical trial. |
|
|
|
|
NovoSeven® RT is approved for use in all ages.b |
|
|
|
| SEVENFACT IS NOT |
| It is only approved for adults and adolescents 12 years and older. |
|
|
|
|
NovoSeven® RT is approved for use before, during, and after surgery and procedures. |
|
|
|
|
NovoSeven® RT is safe when used with Hemlibra.c |
|
|
|
|
NovoSeven® RT is the only rFVIIa with 30+ years of experience controlling severe bleeds.a |
|
|
|
| SEVENFACT IS NOT |
| Three severe bleeds of 468 were studied in the PERSEPT 1 clinical trial. |
|
|
|
|
NovoSeven® RT has over 30 years of clinical and real-world experience in people with hemophilia B with inhibitors.a |
|
| SEVENFACT DOES NOT |
| It was studied in two people with Hemophilia B with inhibitors in the PERSEPT 1 clinical trial. |
|
|
|
NovoSeven® RT is approved for use in all ages.b |
|
| SEVENFACT IS NOT |
| It is only approved for adults and adolescents 12 years and older. |
|
|
|
NovoSeven® RT is approved for use before, during, and after surgery and procedures. |
|
|
|
|
NovoSeven® RT is safe when used with Hemlibra.c |
|
|
|
|
NovoSeven® RT is the only rFVIIa with 30+ years of experience controlling severe bleeds.a |
|
| SEVENFACT IS NOT |
| Three severe bleeds of 468 were studied in the PERSEPT 1 clinical trial. |
|
|
|
aFor people with hemophilia A or B with inhibitors.
bIn people with acquired hemophilia, it is only indicated for adults.
cNovoSeven® RT is the only rFVIIa that has clinical experience for use with Hemlibra. |
|
|
|
When making choices about treatment with your doctor,
the facts speak for themselves. |
|
|
|
|
|
Selected Important Safety Information
|
|
What is the most important information I should know about NovoSeven® RT?
|
|
NovoSeven® RT may cause serious side effects, including:
|
| • |
Serious blood clots that form in veins and arteries with the use of
NovoSeven® RT have been reported
|
|
| • |
Your healthcare provider should discuss the risks and explain the signs and symptoms
of blood clots to you. Some signs of a blood clot may include pain, swelling,
warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or
sudden severe headache and/or loss of consciousness or function
|
|
| • |
Your healthcare provider should monitor you for blood clots during treatment with
NovoSeven® RT
|
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
|
|
Miguel is a devoted dad
with a busy lifestyle. |
He also lives with hemophilia B with inhibitors.
See Miguel’s Story. Miguel has been choosing NovoSeven® RT as his rFVIIa treatment for over 20 years. Why? |
| NovoSeven® RT is: |
|
 |
90% effective in all severe
bleeding episodesa |
|
 |
Room temperature stable
and travel readyb |
|
 |
Fast to mix with our MixPro®
device. Fast to infuse. Fast to
control bleedsc |
|
Approved for use before,
during, and after surgery |
|
Approved for use before,
during, and after surgery |
|
|
Fast to mix with our MixPro®
device. Fast to infuse. Fast to
control bleedsc |
|
|
| aData shown from compassionate use program and 2 clinical studies in patients with hemophilia A or B with or without inhibitors or acquired hemophilia. |
| bNovoSeven® RT should be stored between 36°F and 77°F. |
| cAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered. |
|
|
|
|
|
| What is NovoSeven® RT? |
| NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for: |
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions |
|
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia |
|
| Important Safety Information (cont’d) |
| • |
You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness |
|
| What should I tell my healthcare provider before using NovoSeven® RT? |
| • |
Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots: |
| |
| ◦ |
congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates) |
| ◦ |
are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding |
| ◦ |
history of heart or blood vessel diseases |
|
| • |
Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies |
|
| What are the possible side effects of NovoSeven® RT? |
| • |
The most common and serious side effects are blood clots |
|
| • |
Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction |
|
| Please click here for Prescribing Information. |
| NovoSeven® RT is a prescription medication. |
| You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| PLEASE DO NOT RESPOND TO THIS EMAIL. If you would like to contact us, please click here or call 1‑877‑744‑2579. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
NovoSeven® and MixPro® are registered trademarks of Novo Nordisk Health Care AG.
All other trademarks, registered or unregistered, are the property of their respective owners.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US21NSVN00090 December 2021 |
 |
|
|
|
